Prevalence and predictors of liver steatosis and fibrosis in unselected patients with HIV mono-infection

Digestive and Liver Disease

Volumn 48, Issue 12, 2016, Pages 1471-1477

  Lombardi, Rosa ^a   Sambatakou, Helen ^b   Mariolis, Ilias ^b   Cokkinos, Demosthenis ^c   Papatheodoridis, George V ^d   Tsochatzis, Emmanuel A ^a  

^a ROYAL FREE HOSPITAL   (United Kingdom)

^b HIPPOKRATION HOSPITAL   (Greece)

^c EVANGELISMOS HOSPITAL   (Greece)

^d LAIKO GENERAL HOSPITAL   (Greece)

Author keywords

APRI; Diagnostic accuracy; Elastography; FIB4; NAFLD; Non invasive assessment

Indexed keywords

ADULT; ARTICLE; BIOCHEMICAL ANALYSIS; CLINICAL FEATURE; DIABETES MELLITUS; DYSLIPIDEMIA; FATTY LIVER; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERTENSION; IMMUNOLOGICAL PROCEDURES; LIVER FIBROSIS; MAJOR CLINICAL STUDY; MALE; METABOLIC SYNDROME X; PATIENT HISTORY OF THERAPY; PREDICTIVE VALUE; PREVALENCE; PRIORITY JOURNAL; TRANSIENT ELASTOGRAPHY; ULTRASOUND; VIROLOGY;

EID: 84995451852     PISSN: 15908658     EISSN: 18783562     Source Type: Journal    
DOI: 10.1016/j.dld.2016.08.117     Document Type: Article

References (39)

1. [1] Data Collection on Adverse Events of Anti HIV dSG, Smith, C., Sabin, C.A., et al. Factors associated with specific causes of death amongst HIV-positive individuals in the D:A:D Study. AIDS 24 (2010), 1537–1548.
2. [2] Bica, I., McGovern, B., Dhar, R., et al. Increasing mortality due to end-stage liver disease in patients with human immunodeficiency virus infection. Clinical Infectious Diseases 32 (2001), 492–497.
3. [3] Tsochatzis, E.A., Manolakopoulos, S., Papatheodoridis, G.V., et al. Insulin resistance and metabolic syndrome in chronic liver diseases: old entities with new implications. Scandinavian Journal of Gastroenterology 44 (2009), 6–14.
4. [4] Leow, M.K., Addy, C.L., Mantzoros, C.S., Clinical review 159: human immunodeficiency virus/highly active antiretroviral therapy-associated metabolic syndrome: clinical presentation, pathophysiology, and therapeutic strategies. The Journal of Clinical Endocrinology and Metabolism 88 (2003), 1961–1976.
5. [5] McGovern, B.H., Ditelberg, J.S., Taylor, L.E., et al. Hepatic steatosis is associated with fibrosis, nucleoside analogue use, and hepatitis C virus genotype 3 infection in HIV-seropositive patients. Clinical Infectious Diseases 43 (2006), 365–372.
6. [6] Nunez, M., Hepatotoxicity of antiretrovirals: incidence, mechanisms and management. Journal of Hepatology 44:1 Suppl (2006), S132–S139.
7. [7] Buzzetti, E., Lombardi, R., De Luca, L., et al. Noninvasive assessment of fibrosis in patients with nonalcoholic fatty liver disease. International Journal of Endocrinology, 2015, 2015, 343828.
8. [8] Tsochatzis, E.A., Gurusamy, K.S., Ntaoula, S., et al. Elastography for the diagnosis of severity of fibrosis in chronic liver disease: a meta-analysis of diagnostic accuracy. Journal of Hepatology 54 (2011), 650–659.
9. [9] Tsochatzis, E.A., Castera, L., Assessing liver disease in HIV-HCV coinfected patients. Current Opinion in HIV and AIDS 10:5 (2015), 316–322.
10. [10] Grundy, S.M., Cleeman, J.I., Daniels, S.R., et al. Diagnosis and management of the metabolic syndrome. An American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement. Executive summary. Cardiology in Review 13 (2005), 322–327.
11. [11] Wai, C.T., Greenson, J.K., Fontana, R.J., et al. A simple noninvasive index can predict both significant fibrosis and cirrhosis in patients with chronic hepatitis C. Hepatology 38 (2003), 518–526.
12. [12] Sterling, R.K., Lissen, E., Clumeck, N., et al. Development of a simple noninvasive index to predict significant fibrosis in patients with HIV/HCV coinfection. Hepatology 43 (2006), 1317–1325.
13. [13] Wong, V.W., Vergniol, J., Wong, G.L., et al. Diagnosis of fibrosis and cirrhosis using liver stiffness measurement in nonalcoholic fatty liver disease. Hepatology 51 (2010), 454–462.
14. [14] Mofrad, P., Contos, M.J., Haque, M., et al. Clinical and histologic spectrum of nonalcoholic fatty liver disease associated with normal ALT values. Hepatology 37 (2003), 1286–1292.
15. [15] Brown, T.T., Li, X., Cole, S.R., et al. Cumulative exposure to nucleoside analogue reverse transcriptase inhibitors is associated with insulin resistance markers in the Multicenter AIDS Cohort Study. AIDS 19 (2005), 1375–1383.
16. [16] Vodkin, I., Valasek, M.A., Bettencourt, R., et al. Clinical, biochemical and histological differences between HIV-associated NAFLD and primary NAFLD: a case-control study. Alimentary Pharmacology & Therapeutics 41 (2015), 368–378.
17. [17] Crum-Cianflone, N., Dilay, A., Collins, G., et al. Nonalcoholic fatty liver disease among HIV-infected persons. Journal of Acquired Immune Deficiency Syndromes 50 (2009), 464–473.
18. [18] Nishijima, T., Gatanaga, H., Shimbo, T., et al. Traditional but not HIV-related factors are associated with nonalcoholic fatty liver disease in Asian patients with HIV-1 infection. PloS One, 9, 2014, e87596.
19. [19] Guaraldi, G., Squillace, N., Stentarelli, C., et al. Nonalcoholic fatty liver disease in HIV-infected patients referred to a metabolic clinic: prevalence, characteristics, and predictors. Clinical Infectious Diseases 47 (2008), 250–257.
20. [20] Macias, J., Gonzalez, J., Tural, C., et al. Prevalence and factors associated with liver steatosis as measured by transient elastography with controlled attenuation parameter in HIV-infected patients. AIDS 28 (2014), 1279–1287.
21. [21] Sulyok, M., Makara, M., Rupnik, Z., et al. Hepatic steatosis in individuals living with HIV measured by controlled attenuation parameter: a cross-sectional study. European Journal of Gastroenterology & Hepatology 27 (2015), 679–685.
22. [22] de Ledinghen, V., Douvin, C., Kettaneh, A., et al. Diagnosis of hepatic fibrosis and cirrhosis by transient elastography in HIV/hepatitis C virus-coinfected patients. Journal of Acquired Immune Deficiency Syndromes 41 (2006), 175–179.
23. [23] Vergara, S., Macias, J., Rivero, A., et al. The use of transient elastometry for assessing liver fibrosis in patients with HIV and hepatitis C virus coinfection. Clinical Infectious Diseases 45 (2007), 969–974.
24. [24] Blanco, F., Barreiro, P., Ryan, P., et al. Risk factors for advanced liver fibrosis in HIV-infected individuals: role of antiretroviral drugs and insulin resistance. Journal of Viral Hepatitis 18 (2011), 11–16.
25. [25] Al-Mohri, H., Murphy, T., Lu, Y., et al. Evaluating liver fibrosis progression and the impact of antiretroviral therapy in HIV and hepatitis C coinfection using a noninvasive marker. Journal of Acquired Immune Deficiency Syndromes 44 (2007), 463–469.
26. [26] Morse, C.G., McLaughlin, M., Matthews, L., et al. Nonalcoholic steatohepatitis and hepatic fibrosis in HIV-1-monoinfected adults with elevated aminotransferase levels on antiretroviral therapy. Clinical Infectious Diseases 60 (2015), 1569–1578.
27. [27] Han, S.H., Kim, S.U., Kim, C.O., et al. Abnormal liver stiffness assessed using transient elastography (Fibroscan(R)) in HIV-infected patients without HBV/HCV coinfection receiving combined antiretroviral treatment. PloS One, 8, 2013, e52720.
28. [28] Mendeni, M., Foca, E., Gotti, D., et al. Evaluation of liver fibrosis: concordance analysis between noninvasive scores (APRI and FIB-4) evolution and predictors in a cohort of HIV-infected patients without hepatitis C and B infection. Clinical Infectious Diseases 52 (2011), 1164–1173.
29. [29] Merchante, N., Perez-Camacho, I., Mira, J.A., et al. Prevalence and risk factors for abnormal liver stiffness in HIV-infected patients without viral hepatitis coinfection: role of didanosine. Antiviral Therapy 15 (2010), 753–763.
30. [30] Rivero-Juarez, A., Camacho, A., Merchante, N., et al. Incidence of liver damage of uncertain origin in HIV patients not co-infected with HCV/HBV. PloS One, 8, 2013, e68953.
31. [31] Blackard, J.T., Welge, J.A., Taylor, L.E., et al. HIV mono-infection is associated with FIB-4 – a noninvasive index of liver fibrosis – in women. Clinical Infectious Diseases 52 (2011), 674–680.
32. [32] Sebastiani, G., Rollet-Kurhajec, K.C., Pexos, C., et al. Incidence and predictors of hepatic steatosis and fibrosis by serum biomarkers in a large cohort of human immunodeficiency virus mono-infected patients. Open Forum Infectious Diseases, 2, 2015, ofv015.
33. [33] DallaPiazza, M., Amorosa, V.K., Localio, R., et al. Prevalence and risk factors for significant liver fibrosis among HIV-monoinfected patients. BMC Infectious Diseases, 10, 2010, 116.
34. [34] Sanchez-Conde, M., Montes-Ramirez, M.L., Miralles, P., et al. Comparison of transient elastography and liver biopsy for the assessment of liver fibrosis in HIV/hepatitis C virus-coinfected patients and correlation with noninvasive serum markers. Journal of Viral Hepatitis 17 (2010), 280–286.
35. [35] European Association for the Study of the Liver, Electronic address eee, Asociacion Latinoamericana para el Estudio del H, EASL-ALEH Clinical Practice Guidelines: non-invasive tests for evaluation of liver disease severity and prognosis. Journal of Hepatology 63 (2015), 237–264.
36. [36] Crossan, C., Tsochatzis, E.A., Longworth, L., et al. Cost-effectiveness of non-invasive methods for assessment and monitoring of liver fibrosis and cirrhosis in patients with chronic liver disease: systematic review and economic evaluation. Health Technology Assessment 19 (2015), 1–409 v-vi.
37. [37] Kovari, H., Ledergerber, B., Battegay, M., et al. Incidence and risk factors for chronic elevation of alanine aminotransferase levels in HIV-infected persons without hepatitis b or c virus co-infection. Clinical Infectious Diseases 50 (2010), 502–511.
38. [38] Tsochatzis, E.A., Bosch, J., Burroughs, A.K., New therapeutic paradigm for patients with cirrhosis. Hepatology 56 (2012), 1983–1992.
39. [39] Adams, L.A., Lymp, J.F., St Sauver, J., et al. The natural history of nonalcoholic fatty liver disease: a population-based cohort study. Gastroenterology 129 (2005), 113–121.